|
Feb 25
|
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital
|
|
Feb 25
|
EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025
|
|
Feb 19
|
Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital
|
|
Feb 19
|
EXCLUSIVE: Alzamend Neuro Says Tesla Dynamic Completes Head Coil To Measure Brain Structure Lithium Levels
|
|
Jul 31
|
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
|
|
May 14
|
Alzamend Neuro Announces Initial Closing of Private Placement
|
|
May 9
|
EXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred Shares
|
|
May 9
|
Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million
|
|
May 7
|
Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program
|
|
Apr 2
|
Insiders Are Buying These 11 Penny Stocks
|
|
Nov 13
|
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001
|
|
Oct 2
|
EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder
|
|
Oct 2
|
Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
|